FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the... by Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie-Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Lionel Ades, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier.

Get full text

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study by Jules Higué, Corentin Orvain, Pierre-Yves Dumas, Pierre Peterlin, Marie-Anne Hospital, Sabrina Barrière, Audrey Couturier, Martin Carre, Areti Chantzi, Emmanuelle Tavernier, Éric Delabesse, Audrey Bidet, Anne Bouvier, Marie-Joelle Mozziconacci, Lauren Véronèse, Cédric Pastoret, Sylvie Tondeur, Pascale Flandrin-Gresta, Sébastien Lachot, Marine Cazaux, Sylvain Thépot, Edouard Forcade, Patrice Chevallier, Raynier Devillier, Gaspar Aspas Requena, Sarah Bertoli, Arnaud Pigneux, Christian Récher

Get full text